Protocol Ledger

Federal / NIH · Consolidated Sponsor Hub

National Cancer Institute (NCI): Clinical Trials & FDA Approval Profile

National Cancer Institute (NCI) (Bethesda, MD) sponsors 458 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 318 active protocols (143 recruiting now), 52 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)19.2%
Median Closed Enrollment vs National (145 pts)23 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for National Cancer Institute (NCI)
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)458
Active Pipeline (Recruiting Now)318 (143)
Completed vs Stopped Early52 / 88 (19.2%)
Median Closed Actual Enrollment23 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With National Cancer Institute (NCI)
Hospital Research SiteLocationShared Protocols
NIH Clinical CenterBethesda, MD181
University of Oklahoma Health Sciences CenterOklahoma City, OK173
Washington University and Siteman Cancer CenterSaint Louis, MO140

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by National Cancer Institute (NCI)
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin LPhase IIRECRUITING
NCT06661915A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)Phase IIRECRUITING
NCT03606967Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple NegativPhase IIRECRUITING
NCT04840602Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) fPhase IIRECRUITING
NCT07042295Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the National Cancer Institute (NCI) Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI